BioCentury | Feb 11, 2021
Deals
Next up: Galapagos, Gilead turn to second IPF program, Toledo molecules after $5B deal’s third setback
...By stephen hansen, associate editor A third setback for the $5 billion Galapagos-Gilead deal will now...
...the partners turn their attention to another fibrosis candidate and a Toledo program that targets salt-inducible kinases.Galapagos N.V....
...billion deal that essentially gave Gilead Sciences Inc. (NASDAQ:GILD) ex-EU rights to nearly all of Galapagos’...
...the partners turn their attention to another fibrosis candidate and a Toledo program that targets salt-inducible kinases.Galapagos N.V....
...billion deal that essentially gave Gilead Sciences Inc. (NASDAQ:GILD) ex-EU rights to nearly all of Galapagos’...